TRAIL Gene-armed Oncolytic Poxvirus and Oxaliplatin Can Work Synergistically Against Colorectal Cancer

Overview

Journal Gene Ther

Date 2010 Feb 26

PMID 20182517

Citations 17

Authors

M F Ziauddin

Z S Guo

M E OMalley

F Austin

P J Popovic

M A Kavanagh

J Li

M Sathaiah

P Thirunavukarasu

B Fang

Y J Lee

D L Bartlett

Affiliations

Soon will be listed here.

Abstract

We have explored a unique combination therapy for metastatic colorectal cancer. This strategy combines a potent and new oncolytic poxvirus expressing a membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or TNFSF10) and oxaliplatin (Ox) chemotherapy. We hypothesized that TRAIL expression would increase the efficacy of the oncolytic poxvirus, and that the therapeutic efficacy would be further enhanced by combination with chemotherapy. The cytotoxicity to cancer cells by Ox, oncolytic vaccinia virus (VV) and trail gene-armed VV alone or in combination was tested in vitro. The trail gene armed oncolytic VV-expressed high levels of TRAIL in infected cancer cells and had greater potency as a cytotoxic agent compared with the parent VV. Ox alone exerted concentration-dependent cytotoxicity. In vitro, the combination of the two agents applied at suboptimal concentrations for individual therapy displayed synergy in inducing cancer cells into enhanced levels of apoptosis/necrosis. Western blot analyses were consistent with the notion that TRAIL induced cancer cell death mainly through apoptosis, whereas Ox and vJS6 induced cell death more through non-apoptotic death pathways. In two aggressive colorectal carcinomatosis models derived from human HCT116 and murine MC38 cells, the combination therapy displayed synergistic or additive antitumor activity and prolonged the survival of the tumor-bearing mice compared with either Ox chemotherapy or vvTRAIL-mediated oncolytic gene therapy alone. This combination strategy may provide a new avenue to treating peritoneal carcinomatosis and other types of metastases of colorectal cancer.

Citing Articles

Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy.

Omole R, Oluwatola O, Akere M, Eniafe J, Agboluaje E, Daramola O Front Pharmacol. 2022; 13:1082797.

PMID: 36569326 PMC: 9772532. DOI: 10.3389/fphar.2022.1082797.

The employment of vaccinia virus for colorectal cancer treatment: A review of preclinical and clinical studies.

Ling Q, Zheng B, Chen X, Ye S, Cheng Q Hum Vaccin Immunother. 2022; 18(6):2143698.

PMID: 36369829 PMC: 9746450. DOI: 10.1080/21645515.2022.2143698.

Expression profiling of anticancer genes in colorectal cancer patients and their in vitro induction by riproximin, a ribosomal inactivating plant protein.

Pervaiz A, Saleem T, Kanwal K, Raza S, Iqbal S, Zepp M J Cancer Res Clin Oncol. 2022; 149(8):4825-4837.

PMID: 36251065 DOI: 10.1007/s00432-022-04410-6.

Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits.

Spiesschaert B, Angerer K, Park J, Wollmann G Cancers (Basel). 2021; 13(14).

PMID: 34298601 PMC: 8306439. DOI: 10.3390/cancers13143386.

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy.

Guo Z, Lotze M, Zhu Z, Storkus W, Song X Biomedicines. 2020; 8(7).

PMID: 32664210 PMC: 7400484. DOI: 10.3390/biomedicines8070204.

References

McCart J, Ward J, Lee J, Hu Y, Alexander H, Libutti S . Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001; 61(24):8751-7. View

Duiker E, Mom C, de Jong S, Willemse P, Gietema J, van der Zee A . The clinical trail of TRAIL. Eur J Cancer. 2006; 42(14):2233-40. DOI: 10.1016/j.ejca.2006.03.018. View

Kagawa S, He C, Gu J, Koch P, Rha S, Roth J . Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 2001; 61(8):3330-8. View

Fisher K . Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Curr Opin Mol Ther. 2006; 8(4):301-13. View

Ndozangue-Touriguine O, Sebbagh M, Merino D, Micheau O, Bertoglio J, Breard J . A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene. 2008; 27(46):6012-22. DOI: 10.1038/onc.2008.197. View

Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G . Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst. 2007; 99(23):1768-81. DOI: 10.1093/jnci/djm229. View

Puhlmann M, Brown C, Gnant M, Huang J, Libutti S, Alexander H . Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 2000; 7(1):66-73. DOI: 10.1038/sj.cgt.7700075. View

Song C, Han H, Noh K, Kang T, Park Y, Kim J . Chemotherapy enhances CD8(+) T cell-mediated antitumor immunity induced by vaccination with vaccinia virus. Mol Ther. 2007; 15(8):1558-63. DOI: 10.1038/sj.mt.6300221. View

Galligan L, Longley D, McEwan M, Wilson T, McLaughlin K, Johnston P . Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther. 2005; 4(12):2026-36. DOI: 10.1158/1535-7163.MCT-05-0262. View

10.

Royal R, Pingpank Jr J . Diagnosis and management of peritoneal carcinomatosis arising from adenocarcinoma of the colon and rectum. Semin Oncol. 2008; 35(2):183-91. DOI: 10.1053/j.seminoncol.2007.12.007. View

11.

Zhu H, Zhang L, Huang X, Davis J, Jacob D, Teraishi F . Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther. 2004; 9(5):666-73. DOI: 10.1016/j.ymthe.2004.02.007. View

12.

Cattaneo R, Miest T, Shashkova E, Barry M . Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol. 2008; 6(7):529-40. PMC: 3947522. DOI: 10.1038/nrmicro1927. View

13.

Kaufman H, Lenz H, Marshall J, Singh D, Garett C, Cripps C . Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res. 2008; 14(15):4843-9. DOI: 10.1158/1078-0432.CCR-08-0276. View

14.

Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y . Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. 2008; 15(20):1361-71. DOI: 10.1038/gt.2008.82. View

15.

Elias D, Delperro J, Sideris L, Benhamou E, Pocard M, Baton O . Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004; 11(5):518-21. DOI: 10.1245/ASO.2004.09.008. View

16.

Toscano F, Fajoui Z, Gay F, Lalaoui N, Parmentier B, Chayvialle J . P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene. 2008; 27(30):4161-71. DOI: 10.1038/onc.2008.52. View

17.

Liu T, Taeho Hwang , Park B, Bell J, Kirn D . The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther. 2008; 16(9):1637-42. DOI: 10.1038/mt.2008.143. View

18.

Hoffmann D, Bangen J, Bayer W, Wildner O . Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. Gene Ther. 2006; 13(21):1534-44. DOI: 10.1038/sj.gt.3302806. View

19.

Jalving M, de Jong S, Koornstra J, Boersma-van Ek W, Zwart N, Wesseling J . TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res. 2006; 12(14 Pt 1):4350-6. DOI: 10.1158/1078-0432.CCR-05-2487. View

20.

Lim S, Choi J, Kang H, Han S, Si H . Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int J Cancer. 2009; 126(7):1582-95. DOI: 10.1002/ijc.24853. View